Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
Table 4
Sensitivity and specificity of a decrease in TP53 mutant allele fraction and CA-125 for predicting 6-mo time to progression following one cycle of chemotherapy.